The abstract is read at the publisher; the summary is JClub's.
QW-5-70, a colchicine binding site inhibitor, maintains low-nanomolar antitumor activity in vincristine-resistant BE2C/VCR and paclitaxel-resistant PC-3/TxR models despite P-gp overexpression.
- Why it matters: Efflux-driven resistance and tubulin-dynamics changes limit taxane and vincristine efficacy in high-risk neuroblastoma and castration-resistant prostate cancer, especially under multidrug resistance.
- What they did: The study engineered QW-5-70 to show minimal dependence on P-glycoprotein efflux, then tested tubulin binding, polymerization inhibition, mitotic arrest, and in vitro colony/migration effects across resistant and parental cancer cell lines.
- The result: QW-5-70 suppressed tumor growth in drug-resistant xenografts and showed synergy at selected dose pairs with α-difluoromethylornithine and enhanced apoptosis and clonogenic suppression with MLN8237, with modest weight loss and no evident major-organ histopathology.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.